UNH: A Buying Opportunity Amid Ongoing Recovery
UnitedHealth Group Incorporated (UNH), one of the largest healthcare plan providers in the US, is trading at an attractive price-to-earnings ratio. The stock currently trades at 18.39X forward earnings, below its five-year median P/E of 19.14X and lower than the Zacks Medical, HMOs industry average of 16X.
This suggests that investors are paying a premium for UNH's scale, diversified operations, and strong earnings potential. However, with medical costs improving and the company's adjusted medical care ratio decreasing to 86.7% in the second quarter of 2026 from 89.4% a year earlier, some investors may question whether the stock is undervalued.
Analysts have raised their estimates for UNH's earnings and revenue growth, with the Zacks Consensus Estimate pegged at $19.69 per share for 2026 and $22.42 per share for 2027, representing year-over-year growth of 20.4% and 13.8%, respectively.
The company has also beaten earnings estimates in each of the past four quarters, delivering an average surprise of 12.1%. UNH's strong capital returns, including a dividend yield of 2.36%, add to its appeal as the recovery develops.